UBS raised the firm’s price target on AbbVie (ABBV) to $200 from $195 and keeps a Neutral rating on the shares. AbbVie reported another impressive quarter and the focus now turns to emraclidine and 2025, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie, EvolveImmune Therapeutics announce collaboration
- AbbVie, EvolveImmune announce collaboration, option-to-license agreement
- AbbVie price target raised to $240 from $200 at Cantor Fitzgerald
- AbbVie price target raised to $210 from $195 at BofA
- AbbVie price target raised to $231 from $218 at Morgan Stanley